Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control

Read full text
Authors: Katie Fisher, Mauro Garcia, Giacomo S. Frattari, Chloé M. Naasz, Junlin Zhuo, Míriam Rosás-Umbert, Lisa L. Dietz, Anna Karina Juhl, Emma Falling Iversen, Rikke Olesen, Mariane H. Schleimann, Marie H. Pahus
+30 more Isik S. Johansen, Merle Henderson, Leah Carrere, Isabelle Roseto, Ce Gao, Xiaojuan Yu, Emily J. Fray, Beril Aydin, Donald Lubbeck, J. Lai, Francesco R. Simonetti, Ali Danesh, Itzayana G. Miller, Pilar Mendoza, Julia Niessl, Christian Gaebler, Michael S. Seaman, Daniel E. Kaufmann, Clara Lehmann, Henning Gruell, Florian Klein, Marina F. Caskey, Michel C. Nussenzweig, Martin Tolstrup, R. Brad Jones, Jesper Damsgaard Gunst, Janet D. Siliciano, Mathias Lichterfeld, Robert F. Siliciano, Ole S. Søgaard
Cited by: 2
References: 91

Abstract

Abstract Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.

Fields of Study & Subjects

HIV Research and Treatment CRISPR and Genetic Engineering HIV/AIDS drug development and treatment

Publication details

Journal / source
Nature Immunology
Publisher
Springer Science and Business Media LLC
Volume
27
Issue
4
Pages
812–826
Publication date
3 March 2026
Language
EN